Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

Core Insights - Rakovina Therapeutics is advancing innovative cancer therapies through AI-powered drug discovery and will host a webinar on December 17, 2025 [1][2] - The webinar will feature discussions on creating CNS-penetrant, multi-target cancer therapeutics, using the AI-designed ATR/mTOR inhibitor program as a case study [2] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [4] Company Overview - Rakovina Therapeutics focuses on developing innovative cancer treatments utilizing unique technologies for targeting the DNA-damage response, powered by AI through proprietary platforms like Deep-Docking™ and Enki™ [3][4] - The company emphasizes the accelerated pace of reviewing and optimizing drug candidates due to its AI capabilities [3] Webinar Details - The session titled "From Handshake to Breakthrough" will include a fireside discussion with leaders from Rakovina and Variational AI [2] - An open Q&A session will allow participants to engage directly with both organizations [3]